Lyell Wealth Management LP Buys 291 Shares of Agilent Technologies, Inc. (NYSE:A)

Lyell Wealth Management LP lifted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 3.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,844 shares of the medical research company’s stock after purchasing an additional 291 shares during the period. Lyell Wealth Management LP’s holdings in Agilent Technologies were worth $1,091,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. MV Capital Management Inc. raised its position in Agilent Technologies by 120.7% during the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 105 shares in the last quarter. OFI Invest Asset Management purchased a new position in Agilent Technologies in the 3rd quarter worth approximately $25,000. Baystate Wealth Management LLC increased its holdings in Agilent Technologies by 107.3% in the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock worth $36,000 after buying an additional 133 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Agilent Technologies in the fourth quarter worth approximately $39,000. Finally, Rosenberg Matthew Hamilton lifted its holdings in shares of Agilent Technologies by 51.1% during the 4th quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock valued at $39,000 after buying an additional 96 shares during the period.

Insider Buying and Selling

In related news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Heidi Fields sold 1,658 shares of the business’s stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the sale, the director now owns 54,976 shares of the company’s stock, valued at $7,935,235.84. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Philip Binns sold 2,827 shares of Agilent Technologies stock in a transaction on Monday, March 25th. The shares were sold at an average price of $147.54, for a total value of $417,095.58. Following the sale, the senior vice president now directly owns 9,997 shares of the company’s stock, valued at approximately $1,474,957.38. The disclosure for this sale can be found here. In the last quarter, insiders have sold 61,610 shares of company stock valued at $9,220,333.

Agilent Technologies Stock Down 0.7 %

Shares of A stock traded down $1.01 during trading on Thursday, hitting $136.48. 739,883 shares of the company were exchanged, compared to its average volume of 1,568,316. The firm has a market capitalization of $40.00 billion, a price-to-earnings ratio of 32.74, a P/E/G ratio of 4.22 and a beta of 1.11. Agilent Technologies, Inc. has a twelve month low of $96.80 and a twelve month high of $151.58. The business’s 50-day simple moving average is $141.50 and its 200 day simple moving average is $130.33. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.04 and a current ratio of 2.68.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The firm had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the prior year, the firm earned $1.37 EPS. The business’s revenue was down 5.5% on a year-over-year basis. As a group, analysts forecast that Agilent Technologies, Inc. will post 5.5 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Investors of record on Tuesday, April 2nd were paid a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend was Monday, April 1st. Agilent Technologies’s payout ratio is 22.38%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on A shares. Oppenheimer lifted their price target on shares of Agilent Technologies from $67.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday, March 26th. Stifel Nicolaus upgraded Agilent Technologies from a “hold” rating to a “buy” rating and lifted their price target for the stock from $145.00 to $163.00 in a research report on Friday, April 5th. Evercore ISI raised their price target on Agilent Technologies from $132.00 to $145.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. UBS Group boosted their target price on Agilent Technologies from $130.00 to $155.00 and gave the company a “neutral” rating in a research report on Wednesday, February 28th. Finally, Citigroup boosted their target price on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, five have given a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $141.29.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.